Article Per Year (5 Year)
p-Index From 2021 - 2026
1.048
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia MNJ (Malang Neurology Journal) Jurnal Keperawatan Padjadjaran Magna Neurologica Neurona
Tejomukti, Teddy
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Magna Neurologica

 1 
Olfactory Neuroblastoma with Intracranial Extension Nurwahyu Putra Romadhani, Andry; Imanuddin, Iqbal; Tejomukti, Teddy; Watanabe, Yasuhiro; Murakami, Takenobu; Tajiri, Yuki
Magna Neurologica Vol. 2 No. 2 (2024): July
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v2i2.1164

Abstract

Background: Olfactory Neuroblastoma (ONB), so called esthesioneuroblastoma, is a rare malignant tumor of the sinonasal tract. ONB represents 6.3% of all sinonasal tract malignancies, with a prevalence of 0.4 cases per million population. These tumors are slow-growing and there may be intracranial extension of the tumor. Nasal obstruction, anosmia, recurrent epistaxis and pain are typical early manifestations. Imaging studies are essential in determining tumor extension and surgical planning of ONB. Endonasal biopsy is required to confirm the diagnosis of ONB. The case provides a basis for discussion of ONB and highlights the possibility of extension of this tumor. Case: A 45-year-old male presented with a generalized clonic seizure, conjugate eye deviation, and pre-seizure headache. Post-seizure, the patient was unconscious and incontinent, later appearing conscious but confused. The patient had a history of seizures at home and in the ER, along with occasional headaches over the past year. The patient described nasal congestion, decreased smell, and recurrent nosebleeds, having undergone ethmoidectomy in 2020 for papilloma. Discussion: The patient experienced symptoms of seizures, headache, and nasal disturbances. Olfactory neuroblastoma (ONB) tumor was detected after comprehensive examination. Treatment involves multimodal therapy, including surgery, chemotherapy, and radiotherapy, with prognosis depending on tumor stage and grade. Conclusion: Early diagnosis of ONB is necessary to prevent further tumor progression. Intracranial extension of the ONB should be carefully investigated. Imaging as well as histopathological and immunohistochemical examinations are very helpful in identifying the location, metastasis and degree of malignancy of the tumor.
Comparison of Seizure-Free Rates Between Levetiracetam and Phenytoin Administration in Seizure Patients with Brain Metastases Tumor (BM) During Period January 2023-December 2024 Hapsari, Dhiandra Dwi; Tejomukti, Teddy; Nastiti, Ranum Anggun
Magna Neurologica Vol. 3 No. 1 (2025): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v3i1.1726

Abstract

Background: Brain metastase tumor (BM) is the most frequently found intracranial tumor. The prevalence of seizures in BM ranges from 30%-50%. One of the treatments for seizure patients with BM is the administration of Anti-Epileptic Drugs (AED). The latest neuropharmacology now makes Levetiracetam (LEV) the first-line choice in BM cases compared to phenytoin (PHT), which was previously often used in BM cases. Objective: This study aims to compare seizure-free rates in patients with seizures on BM who received PHT or LEV treatment at Regional General Hospital Dr. Moewardi Surakarta from January 2023 – December 2024. Methods: An observational study using a cross-sectional method with a retrospective approach. Patients included were patients with BM who experienced seizures and received AEDs, either PHT 2x100 mg or LEV 2x500 mg, for a minimum duration of 6 months during the period January 2023–December 2024. Results: There were 50 research subjects with an age range of 38-67 years. The independent T-Test showed a significance value of 0.007 < value (0.05). In the group of patients given PHT, the seizure-free rate was 6.83±1.26 a (7 months), while in the LEV group, it was 9.02±0.85 b (9 months). Conclusion: A longer seizure-free rate in research subjects with LEV than PHT was found. This result is to previous research regarding the effectiveness of LEV as the leading choice in seizure patients with BM.
Co-Authors Aninditha, Tiara Bambang Purwanto Budianto, Pepi Dhiandra Dwi Hapsari Diah Kurnia Mirawati Dono Indarto Hafizhan, Muhammad Hambarsari, Yetty Hamidi, Baarid Luqman Hamka, Muhammad Farid Hutabarat, Ervina Arta Jayanti Iqbal Imanuddin Muhammad, Faizal Murakami, Takenobu Nastiti, Ranum Anggun Novian Anindito Santosa Nurwahyu Putra Romadhani, Andry Prabaningtyas, Hanindia Riani Rahman, Awalil Rifqi Kurnia Ristinawati, Ira Rivan Danuaji Soetrisno Stefanus Erdana Putra Subandi Subandi SUROTO Suroto Suroto Tajiri, Yuki Tedjo, Raden Andi Ario Tristan, Christopher Daniel Vitri Widyaningsih Watanabe, Yasuhiro